Innovative Research Award
Alissa Groenendijk
Princess Máxima Center for Pediatric Oncology
The Innovative Research Award recognizes researchers whose scholarly activities demonstrate meaningful scientific advancement, methodological rigor, and measurable research influence. Alissa Groenendijk has contributed to the field of pediatric oncology through published research focused on childhood cancer, clinical outcomes, and translational biomedical investigations. Her scholarly profile reflects peer-reviewed publications, citation impact, and engagement with internationally indexed research databases, providing evidence of an active academic career.[1]
Abstract
Alissa Groenendijk’s academic profile illustrates participation in pediatric oncology research emphasizing clinically relevant questions related to childhood malignancies, patient management, and translational science. Her publications indexed in Scopus indicate consistent scientific engagement and measurable citation performance. These indicators support consideration for recognition through research excellence awards that acknowledge scholarly productivity and scientific contribution.[1][2]
Keywords
Innovative Research Award, Alissa Groenendijk, Pediatric Oncology, Childhood Cancer, Wilms Tumor, Translational Medicine, Clinical Oncology, Cancer Research, Molecular Oncology, Pediatric Cancer Research, Princess Máxima Center for Pediatric Oncology, Scientific Research Excellence, Academic Recognition, Scopus Author, ORCID Researcher, Biomedical Research, Oncology Publications, Research Impact, Citation Analysis, World Top Scientist Awards.
Introduction
Research in pediatric oncology requires multidisciplinary collaboration, evidence-based clinical investigation, and continuous improvement in patient outcomes. Scholars working within this discipline contribute to advances in diagnosis, treatment strategies, survivorship, and quality of care. Academic recognition programs evaluate researchers using publication quality, citation metrics, scientific influence, and contributions to knowledge dissemination.[3]
Research Profile
Affiliated with the Princess Máxima Center for Pediatric Oncology in the Netherlands, Alissa Groenendijk has developed an academic portfolio represented through indexed publications and international scholarly visibility. According to the available Scopus profile, her research output comprises eight indexed documents with more than one hundred citations and an h-index of four, reflecting growing academic influence within her specialization.[1]
Research Contributions
Her published work contributes to pediatric oncology by addressing clinically meaningful research questions relevant to childhood cancers and translational medicine. Such investigations assist healthcare professionals and researchers in understanding disease mechanisms, evaluating therapeutic approaches, and supporting evidence-informed clinical practice. The integration of collaborative research strengthens the broader scientific understanding of pediatric cancer management.[2]
Publications
The available publication record demonstrates contributions to peer-reviewed scientific literature indexed within international bibliographic databases. Publications have accumulated citations from subsequent studies, indicating continued scholarly engagement with the reported findings. Many biomedical articles are assigned Digital Object Identifiers (DOIs), enabling persistent identification and long-term accessibility within scholarly communication.[2][4]
Research Impact
Citation counts, h-index values, publication records, and institutional affiliations collectively provide commonly accepted indicators for evaluating research influence. Although bibliometric measures should be interpreted alongside qualitative scientific assessment, they remain valuable tools for recognizing sustained scholarly productivity and academic visibility.[1][3]
Award Suitability
Based on publicly available scholarly indicators, Alissa Groenendijk demonstrates characteristics frequently considered during evaluations for academic recognition, including peer-reviewed publications, measurable citation performance, institutional research affiliation, and contributions to pediatric oncology. Final award determinations remain subject to the eligibility requirements, review procedures, and evaluation criteria established by the World Top Scientist Awards.[5]
Conclusion
The academic profile presented here summarizes the publicly available scholarly information associated with Alissa Groenendijk and highlights research activity within pediatric oncology. The combination of indexed publications, citation metrics, institutional affiliation, and ongoing scientific engagement reflects an active contribution to biomedical research while supporting consideration for professional recognition through competitive academic award programs.[1]
External Links
References
- Groenendijk, A., Mavinkurve-Groothuis, A. M. C., van Tinteren, H., de Krijger, R. R., Al-Saadi, R., Pritchard-Jones, K., Ramírez-Villar, G. L., Vujanic, G., Melchior, P., Godzinski, J., et al. (2026). Characteristics and outcome of patients with second and subsequent relapse of Wilms tumour: A report from the SIOP Renal Tumour Study Group. EJC Paediatric Oncology.
https://doi.org/10.1016/j.ejcped.2026.100520
- Groenendijk, A., Aronow, B. J., Cost, N., Cajaiba, M., Renfro, L. A., Perlman, E. J., Dyer, L., Smolarek, T. A., Mullen, E. A., Pervaiz, S., et al. (2026). Integrated molecular, genomic, and clinical characterization of pediatric and adolescent translocation renal cell carcinoma: A report from the Children’s Oncology Group. Biomedicines, 14(5), 955.
https://doi.org/10.3390/biomedicines14050955
- Groenendijk, A., van Tinteren, H., de Krijger, R. R., Vujanic, G., Al-Saadi, R., Pritchard-Jones, K., Ramírez-Villar, G. L., Melchior, P., Godzinski, J., Schenk, J.-P., et al. (2025). Outcome of patients with a first relapse after intermediate- or high-risk Wilms tumor, treated according to SIOP WT 2001/UK-IMPORT study: A report from the SIOP Renal Tumour Study Group. Urologic Oncology: Seminars and Original Investigations.
https://doi.org/10.1016/j.urolonc.2025.05.018
- Groenendijk, A., Drost, J., Mavinkurve-Groothuis, A. M. C., van Grotel, M., Janssens, G. O., Littooij, A. S., van der Steeg, A. F. W., van den Heuvel-Eibrink, M. M., Kester, L., & de Krijger, R. R. (2025). Gene expression analysis of (paired) primary and relapsed Wilms tumor samples to unravel the underlying factors driving tumor recurrence. Cancer Medicine.
https://doi.org/10.1002/cam4.70969
- van Belzen, I. A. E. M., van Tuil, M., Badloe, S., Strengman, E., Janse, A., Verwiel, E. T. P., van der Leest, D. F. M., de Vos, S., Baker-Hernandez, J., Groenendijk, A., et al. (2022). Molecular characterization reveals subclasses of 1q gain in intermediate-risk Wilms tumors. bioRxiv (Preprint).
https://doi.org/10.1101/2022.08.12.503742